Literature DB >> 3161738

Metabolism of thymoxamine. I. Studies with 14C-thymoxamine in rats.

K O Vollmer, B Liedtke, A Poisson, A von Hodenberg, W Steinbrecher.   

Abstract

Thymoxamine is rapidly and completely absorbed in rats. It is a prodrug which does not enter the systemic circulation in its unchanged form. After either oral or intravenous administration it undergoes rapid and intense metabolism involving four biotransformation reactions: Enzymatic hydrolysis to the corresponding phenol (metabolite I), Monodemethylation to metabolite II, Sulfate conjugation of I and II (metabolites III and IV) and Conjugation of I and II with glucuronic acid (metabolites V and VI). With these 6 metabolites identified approximately 95% of the radioactivity can be accounted for in plasma, urine and bile. Whereas the systemic availability of I and II is low, III and IV show high bioavailability. Metabolites I to IV are pharmacologically active, while III and IV are less potent than I and II. The radioactivity distribution in tissues is different after oral and intravenous administration consistent with the higher portion of unconjugated metabolites in the body after administration by parenteral route. Although 60% of the labelled compounds is eliminated via bile, the radioactive compounds are almost completely excreted in the urine after both routes of administration. This demonstrates complete reabsorption of the biliary metabolites. Secondary peaks of radioactivity in plasma and organs at 4 hours are explained by the participation of the metabolites in the enterohepatic circulation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3161738     DOI: 10.1007/BF03189698

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  [Pharmacology of sympatholytic 6-acetoxy-thymoxy-ethyldimethylamine].

Authors:  K GREFF; H J SCHUMANN
Journal:  Arzneimittelforschung       Date:  1953-07

2.  Competitive blockade of adrenergic alpha-receptors and histamine receptors by thymoxamine.

Authors:  A T Birmingham; J Szolcsányi
Journal:  J Pharm Pharmacol       Date:  1965-07       Impact factor: 3.765

3.  [Sympatholytic properties of some thymol ethers].

Authors:  K Hcredner; R Graebner
Journal:  Arzneimittelforschung       Date:  1967-03

4.  [Clinical-pharmacological study on the effectiveness of acetic acid-(4-(2-dimethylamino-ethoxy)-5-isopropyl-2-methyl-phenyl)ester-HCl (moxisylyt)].

Authors:  A Wasilewski
Journal:  Arzneimittelforschung       Date:  1971-08

5.  Determination of subtype selectivity of alpha-adrenergic antagonists: comparison of selective and nonselective radioligands.

Authors:  T N Lavin; B B Hoffman; R J Lefkowitz
Journal:  Mol Pharmacol       Date:  1981-07       Impact factor: 4.436

6.  [Limitations of surgical and possibilities of conservative therapy of peripheral arterial circulation disorders].

Authors:  H Rech
Journal:  Med Welt       Date:  1971-08-21

7.  Metabolism of thymoxamine. II. Studies with 14C-thymoxamine in man.

Authors:  K O Vollmer; A Poisson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jan-Mar       Impact factor: 2.441

8.  Metabolism of thymoxamine. III. Structure elucidation of the metabolites and interspecies comparison.

Authors:  K O Vollmer; A von Hodenberg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

9.  In vitro and in vivo alpha-blocking activity of thymoxamine and its two metabolites.

Authors:  M H Creuzet; G Prat; A Malek; F Fauran; J Roquebert
Journal:  J Pharm Pharmacol       Date:  1980-03       Impact factor: 3.765

10.  Metabolism of thymoxamine: identification of metabolites in rat.

Authors:  C Feniou; B Neau; G Prat; C Cheze; F Fauran; J Roquebert
Journal:  J Pharm Pharmacol       Date:  1980-02       Impact factor: 3.765

View more
  6 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  GLC method for the quantification of metabolites of thymoxamine in human plasma.

Authors:  H Hengy; A Von Hodenberg; K O Vollmer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

3.  Metabolism of thymoxamine. II. Studies with 14C-thymoxamine in man.

Authors:  K O Vollmer; A Poisson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jan-Mar       Impact factor: 2.441

4.  Metabolism of thymoxamine. III. Structure elucidation of the metabolites and interspecies comparison.

Authors:  K O Vollmer; A von Hodenberg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

5.  Pharmacokinetics of thymoxamine in rabbits after ophthalmic and intravenous administration.

Authors:  I Aldana; E González-Peñas; D Fos; L Bruseghini; A Esteras; N Ceppi Monti; V Gianesello
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Apr-Jun       Impact factor: 2.441

6.  Pharmacokinetics of a prodrug thymoxamine: dose-dependence of the metabolite ratio in healthy subjects.

Authors:  C Marquer; J H Trouvin; J Y Lacolle; C Dupont; C Jacquot
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jul-Sep       Impact factor: 2.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.